What Is GLP-1? Complete Guide to the Hormone, the Drugs, and What They Do

GLP-1 is, technically, a 30-amino-acid peptide hormone your gut releases after you eat. Practically, it's the molecule behind Ozempic, Wegovy, Mounjaro, Zepbound and the entire wave of weight-loss drugs that transformed obesity medicine starting in the mid-2010s.

This guide is the pillar to the whole GLP-1 cluster — the natural hormone, the agonist drugs, what they do, who they're for, and what they aren't. Every other article on PeptideStat about specific GLP-1 drugs links back here.

The hormone

GLP-1 (glucagon-like peptide-1) is an incretin — a hormone released by intestinal L-cells when food arrives in the gut. It does several things:

1. Stimulates insulin release (glucose-dependent) — pancreatic beta cells release more insulin when blood sugar is rising
2. Suppresses glucagon — reducing the liver's release of stored sugar
3. Slows gastric emptying — food leaves the stomach more slowly, which extends satiety
4. Acts on appetite centers in the brain — reducing hunger and "food noise"
5. Decreases caloric intake as a downstream effect

Natural GLP-1 has a half-life of about two minutes — it's broken down almost immediately by the enzyme DPP-4. That's why a hormone with such useful effects didn't translate into a drug until scientists figured out how to engineer it to last longer.

The drugs: GLP-1 receptor agonists

A GLP-1 receptor agonist is a synthetic molecule that mimics natural GLP-1 but is built to resist DPP-4 breakdown and stay active in the body for hours or days. The major approved drugs:

| Drug | Brand names | Class | Approved for | | --- | --- | --- | --- | | Semaglutide | Ozempic (injection), Wegovy (injection), Rybelsus (oral) | GLP-1 only | T2D (Ozempic, Rybelsus); chronic weight management, CV risk, MASH (Wegovy) | | Tirzepatide | Mounjaro, Zepbound | Dual GLP-1 / GIP | T2D (Mounjaro); chronic weight management, OSA (Zepbound) | | Liraglutide | Victoza, Saxenda | GLP-1 only | T2D (Victoza); chronic weight management (Saxenda) | | Dulaglutide | Trulicity | GLP-1 only | T2D | | Exenatide | Byetta, Bydureon | GLP-1 only (short-acting) | T2D |

The newer triple-agonist Retatrutide (GLP-1 / GIP / glucagon) extends this further but is still in Phase 3 trials — not yet approved. See our Retatrutide guide.

How GLP-1 agonists work for weight loss

When you inject a long-acting GLP-1 agonist weekly:

• It binds GLP-1 receptors continuously — slowing gastric emptying around the clock
• Satiety signals fire earlier in meals, so portions naturally shrink
• "Food noise" (intrusive food thoughts) quiets — many patients report this as the biggest qualitative change
• Caloric intake drops by 20–35% on average in trials
• Weight loss follows, plateauing around 15% body weight for semaglutide and 21% body weight for tirzepatide at top doses

Real-world results vary substantially, but the trial averages are what the marketing numbers come from.

For the head-to-head, see best GLP-1 for weight loss.

Side effects, in plain terms

GLP-1 side effects are predictable, dose-related, and almost entirely gastrointestinal:

• Nausea — most common, especially during dose escalation. Usually resolves over 4–8 weeks.
• Vomiting — less common, similar pattern
• Diarrhea or constipation — variable; usually manageable
• Reflux / belching — common at higher doses
• Injection site reactions — mild, transient
• Decreased appetite — the intended effect, but it can go too far; some patients struggle to eat enough calories or protein
• Fatigue — common in early weeks
• Gallbladder issues — documented; risk rises with rapid weight loss
• Pancreatitis — rare but serious; medical emergency
• Muscle loss — real concern with rapid weight loss; protein intake and resistance training matter
• "Ozempic face" — colloquial term for the volume loss visible after significant weight reduction
• Thyroid C-cell tumors — boxed warning based on rodent studies; contraindicated in personal or family history of MTC or MEN-2

For the full safety profile, see GLP-1 side effects.

Who qualifies for a GLP-1 prescription

The FDA-label eligibility for weight-management GLP-1s (Wegovy, Zepbound, Saxenda):

• BMI ≥ 30 (obesity), OR
• BMI ≥ 27 with at least one weight-related condition (e.g., hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea)

For T2D-indicated GLP-1s (Ozempic, Mounjaro, Trulicity, Rybelsus):

• Diagnosis of type 2 diabetes

Most legitimate prescribers — in-person or telehealth — follow these criteria. Anyone prescribing without meeting at least one is off-label and outside standard practice.

Who probably shouldn't take a GLP-1

• Personal or family history of medullary thyroid carcinoma or MEN-2
• Personal history of pancreatitis
• Severe gastroparesis already
• Pregnancy or planning pregnancy in the near term
• Active or recent eating disorder
• Type 1 diabetes (different pathophysiology; GLP-1s aren't a T1D treatment)

Cost and access in 2026

The honest range for monthly cost of a GLP-1 in 2026:

• With commercial insurance + manufacturer copay card: $25/month
• Cash-pay manufacturer direct (LillyDirect, NovoCare): $349–$650
• Compounded via 503A pharmacy: $199–$349
• Brand-name cash-pay no discount: $968–$1,400

For the full price math, see GLP-1 cost. For the cheapest legal route, see cheapest GLP-1 for weight loss.

What GLP-1 isn't

A few common confusions worth clearing up:

• GLP-1 ≠ insulin. GLP-1 agonists cause a glucose-dependent insulin release; they aren't insulin themselves.
• GLP-1 ≠ HGH or growth hormone. Different hormone family entirely. Sermorelin is a GH secretagogue — different drug class. See our Sermorelin guide.
• "GLP-1 inhibitor" is usually a search typo. People searching for "GLP-1 inhibitors" usually mean "GLP-1 receptor agonists" or the unrelated SGLT2 inhibitors. See GLP-1 vs SGLT2 inhibitors.
• Berberine and other supplements aren't GLP-1 drugs. They may have some metabolic effects but they don't produce GLP-1-class weight loss.

What happens when you stop taking a GLP-1

Most people who stop a GLP-1 regain some — often a majority — of the lost weight within a year. The trials that studied discontinuation found significant rebound: typically 50–70% of the lost weight returns over 12 months without continued treatment or sustained lifestyle change.

This is why GLP-1s for weight management are framed as long-term treatments for a chronic condition, not short-term diet pills.

The next generation

Drug development hasn't stopped at semaglutide and tirzepatide. The near-future pipeline:

• Retatrutide (Eli Lilly) — triple agonist (GLP-1 / GIP / glucagon). Phase 2 numbers exceeded all current agents; Phase 3 (TRIUMPH program) reading out through 2026. NDA expected late 2026, approval ~2027–2028. See our Retatrutide guide.
• Survodutide (Boehringer Ingelheim) — dual GLP-1/glucagon agonist, late-stage trials for obesity and MASH
• CagriSema (Novo Nordisk) — combination of cagrilintide (amylin analog) and semaglutide; Phase 3
• Oral GLP-1 agonists beyond Rybelsus — Pfizer's danuglipron, Eli Lilly's orforglipron and others in development

FAQ

Is GLP-1 the same as Ozempic? GLP-1 is the hormone. Ozempic is the brand name for semaglutide, one specific GLP-1 receptor agonist drug.

What does GLP-1 stand for? Glucagon-Like Peptide-1.

Is there a natural way to increase GLP-1? Protein-rich and fiber-rich meals modestly increase endogenous GLP-1 release. Supplements claiming to "boost GLP-1" don't replicate the effect of GLP-1 receptor agonist drugs.

How long does it take to see GLP-1 weight loss? Most patients notice reduced appetite within the first 1–2 weeks. Meaningful weight loss typically appears by 6–8 weeks; trial-average weight loss is reached around 56–72 weeks.

Is GLP-1 safe long-term? Trial evidence out to ~3 years is broadly reassuring. Longer-term data is still accumulating. Long-term use is the expected pattern for chronic-condition treatment.

---

This article is for educational purposes only and is not medical advice. GLP-1 medications are prescription drugs and should be used only under the supervision of a qualified healthcare professional. Articles may contain affiliate links — we may earn a commission at no extra cost to you.